| |
Demographics
|
Baseline variables
|
Follow-up variables
|
---|
| |
Age
|
Disease duration
|
N. comorbidities
|
ESR
|
TJC
|
SJC
|
PGA
|
DAS-28
|
Depression
|
Anxiety
|
ESR
|
TJC
|
SJC
|
PGA
|
DAS-28
|
---|
|
Age
|
-
| | | | | | | | | | | | | | |
|
Disease duration
|
0.29*
|
-
| | | | | | | | | | | | | |
|
Number of comorbidities
|
0.32
|
0.22
|
-
| | | | | | | | | | | | |
Baseline Variables
|
ESR
|
0.10
|
0.27*
|
0.07
|
-
| | | | | | | | | | | |
TJC
|
−0.13
|
0.07
|
0.13
|
−0.13
|
-
| | | | | | | | | | |
SJC
|
−0.14
|
−0.03
|
0.03
|
0.11
|
0.54**
|
-
| | | | | | | | | |
PGA
|
−0.20
|
0.16
|
0.25
|
0.18
|
0.64***
|
0.45***
|
-
| | | | | | | | |
DAS-28
|
−0.17
|
0.13
|
0.03
|
0.44***
|
0.41**
|
0.47***
|
0.60***
|
-
| | | | | | | |
Depression
|
−0.26
|
0.12
|
−0.16
|
0.04
|
0.25
|
0.23
|
0.44**
|
0.40**
|
-
| | | | | | |
Anxiety
|
−0.29*
|
−0.02
|
−0.11
|
0.03
|
0.16
|
0.19
|
0.31*
|
0.29*
|
0.76***
|
-
| | | | | |
Follow-up Variables
|
ESR
|
0.10
|
0.33*
|
−0.01
|
0.86***
|
−0.13
|
−0.02
|
0.16
|
0.37**
|
0.03
|
0.03
|
-
| | | | |
TJC
|
0.18
|
0.23
|
0.15
|
−0.18
|
0.24
|
0.00
|
0.32*
|
0.07
|
0.34*
|
0.23
|
0.02
|
-
| | | |
SJC
|
0.33*
|
0.32*
|
0.16
|
0.23
|
0.01
|
0.01
|
0.11
|
0.07
|
0.16
|
0.08
|
0.44**
|
0.64***
|
-
| | |
PGA
|
0.19
|
0.33*
|
0.03
|
0.11
|
0.29*
|
0.19
|
0.46***
|
0.45***
|
0.45***
|
0.43**
|
0.22
|
0.37**
|
0.23**
|
-
| |
DAS-28
|
−0.03
|
0.21
|
0.06
|
0.36**
|
0.07
|
0.08
|
0.35*
|
0.80***
|
0.39**
|
0.33*
|
0.47**
|
0.33*
|
0.36*
|
0.61***
|
-
|
- ESR erythrocyte sedimentation rate, TJC tender joint count, SJC swollen joint count, PGA patient global assessment, DAS-28 28 joint disease activity scale, HADS-D hospital anxiety and depression scale depression subscale, HADS-A hospital anxiety and depression scale anxiety subscale. * p < 0.05, **p < 0.01, ***p < 0.001